Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

I am holding too,
rock on BPRG

ps
I have been looking at ,,,,
MT.
PUB
SBRY
IMP
PCI
ALV
CWE

anybody following them?

I am in (MT. PUB SBRY (& BPRG obv.)
MT. is a punt, but lets see ?
I was in and out of old MT. (Airtours) with a bit over 100% clear profit so some
sentimental betting going on also

good luck all

nemetode

as your so close to gh
what does he say about the patent action?

a bprg holder.

GH is very confident but won't be drawn to anything as it is all very confidential and sensitive.I have to respect his views on that and also that he is a very busy man and just let him carry on with his business of securing earning enhancing deals.

Anyway this is from tiger on ample,
Why would anyone buy stock at 1.10 and then sell it at a lower price?
The CEO said he would like a note by the end of March...so we were all to believe it would happen.
Having spoken to my contact as CS....the reason it could not be done was a couple of important deals (earnings enhancing ones) that were not signed off.
With any company in it;s early days, getting a true valuation is very difficult and some times share prices are driven too high.
I know that at the last presentation given to the buyers of the stock in the last placing...the shares were deemed to be VERY cheap at 1.10
This was the reason they wanted more.

We small investors have not yet got that info....officially....however a few leaks do crep from Bio now and again, and what you read with some of the posters on ADVFN is VERY close to the truth.
If i were to take any position in this stock it would be LONG.
To go SHORT could be costly.
I hope you are around at the end of APRIL and expect you to post then....who was right or wrong!!

not being funny nematode, but the last post you made is exactly the same one that was posted about a month ago. again just my opinion, i just hope that the comments you make are not fantasy and you really do know this chap, either way i dont pay the slightest bit of attention. again IMHO

cheers questy

Robin I use www.sharecrazy.com which also has some useful threads and info. ADV bit too full on for me .

best of luck

Wiz

Sorry mark,I never ever posted the same post a month ago.You're being a prat!!!

Lol nematode , you talk through your butt IMO.

Article in Shares Mag today...."plenty more deals to come"

Thats down to Bullie trying to boost his pension fund :-)

From all the dross on ADVFN you do get one or two gems, this is one of them

As posted by Mr K

Hi,

Its interesting to read the discussion about Stanelco and BioProgress. I made my mind up a long time ago, but ultimately time will tell.

There are many people who say, When will they get it? referring to the city and its apparent neglect in picking up on the prospects of BioProgress sooner. What I wanted to find out is exactly to what extent has the city missed out on BioProgress? BioProgress is after all very much considered a bulletin board stock, i.e. a large following of retail investors.

The fact is that it would appear that the city is far slower than retail investors in spotting unique companies with realistic chances of becoming big winners. 3DM is another example where a few city fund managers will have it on their radars but not follow their interest up by daring to invest. Perhaps this is more understandable with 3DM with the illiquid state of stock. But with BioProgress there are no excuses.

So, which fund managers have been shrewd enough to spot the massive potential of BioProgress? Looking back to my notes of December show that Ormiston-Gore Securities Ltd held 4.2% of the company and Jade Partnership International held 3.31%. These are the only institutions with declarable stakes above 3%.

So does Jade Partnership International have a shrewd fund manager whose ideas I should be looking to follow more closely? Far from it actually, as BioProgress Technical Director Malcolm David Brown is a director and a controlling shareholder of Jade! No prizes therefore for wondering exactly how Jade heard of BioProgress. It is worth noting that Jade owed BioProgress 162,150 at 31st December 2003, but they have now reduced their stake below 3%, which would have generated them the equity owed to BioProgress. It does take in depth research to sometimes work out exactly why institutions might sell.

As for knowing who Ormiston-Gore Securities are, well this is interesting as again it is not a city institution. The registered address for the company is in Cambridge and takes us to Mills & Reeve Solicitors. The former name of Ormiston-Gore was in fact M&R 907 Ltd. BioProgress is Cambridge based, so once again this disclosable holding points to someone in the know with BioProgress.

Today, the institution with a holding above 3% is just Schweco Nominees Ltd with 5.74%. Is there then the possibility that both Jade Partnership International and Ormiston-Gore Securities Ltd have been selling now that they hold less than 3%? The answer is possibly, we simply do not know, as dilution has occurred with two fund raisings.

Graham Hind said that with the recent institutional placing there were two new institutions involved; bringing the total to eight, no name no packdrill so far. A friend told me that recently there was an institution selling when the price was around 105p, 5p below the 110p placing price, theres a surprise! So therefore I would guess that one of the institutions who got hold of stock in quantity at the placing at 110p has now sold all or part of their holding, Ive been told that they have finished selling though.

I believe that the city is slowly waking up to BioProgress, there are now far fewer uncertainties than there were even just three months ago.

One fund manager who I do respect is Patrick Evershed of New Star, who holds 1.7% of BioProgress, having first brought at 44p, good man!

Colin Blackbourn held stock in BioProgress when it was on the OTC BB exchange, Ill have to try and see if he still has any, if not, why not?!

And what of the house broker Collins Stewart. Have they been holding the price back in order to get their own clients on board? Quite possibly, but shhhhh Im not allowed to say that!

To conclude, I believe that the city is slowly realising the opportunity that BioProgress presents. There are at least seven or eight institutions that currently have a holding in BioProgress, all below the 3% disclosable level. Over the coming months I would expect more institutions to buy into the story, and I also expect to see a higher share price.

Oh, incidentally I hear that Graham Hind is working alongside the CS analyst who is writing the report on BioProgress. Now that can be no bad thing, can it?! Interesting times around the corner.

Best Wishes,

Mr K

Thanks Janus....clarifies things.

steadily we go marching upwards!!!

Maybe some good news around the corner, anyone going to the AGM? Are we expecting another announcement at AGM or will that be held back, makes sense to
release just before or at AGM or am I being stupid?

Watch out for good news this week.

cheers Gf.

OK mate!!!

Any reason for the drop today are the MM's playing games again?

is that the same good news that mediwatch were supposed to be getting. Which is now 3 months ago!!!!!!!!!!!!!!!!!!

Is anyone going to the AGM today? Would appreciate some feedback! Are the MM's playing games again with the price? Do we think the price may rise after the AGM?

Taken from BioProgress website 21 April 2004
AGM statement and senior management appointment at BioTec Films LLC

BioProgress plc, a provider of innovative delivery mechanisms for the pharmaceutical oral dosage markets, announces today that, at the Company’s Annual General Meeting, held earlier today, all resolutions before the meeting were duly passed.

Speaking at the meeting in London, Peter Glynn-Jones, Chairman of BioProgress, said: “BioProgress has continued its excellent progress to date in the first quarter of the current financial year. Central to our progress during this period has been the acquisition of the Aqua Film assets in the United States, now renamed BioTec Films LLC, which will contribute immediate revenues and help accelerate the delivery of our technologies to our customers.”

Mr Glynn-Jones also informed Shareholders that George Tidy has been appointed as Senior Vice President Operations at BioTec Films LLC, the wholly owned film manufacturing subsidiary that BioProgress recently established following the acquisition of certain assets from Aquafilm LLC, based in Tampa Florida USA.

Mr. Tidy is a qualified Plant Engineer with thirty years experience in pharmaceutical operations, as well as Research and Development operational development. He worked for R. P. Scherer Corporation (now part of Cardinal Health, Inc.) between 1974 and 2001 in various senior engineering positions, developing and improving gelatin and starch based encapsulation technology, including major roles in establishing entire gelatin capsule manufacturing facilities in Korea and Egypt. Mr. Tidy was also a member of R. P. Scherer’s global process improvement team.

Between 1997 and 2001, Mr. Tidy was Plant Director Operations for the R. P. Scherer Zydis pharmaceutical manufacturing process and, in 2001, he was appointed Director New Technologies Operations Development for Cardinal Health, with special responsibility for the development of radio frequency capsule manufacturing processes in the collaborative venture between Cardinal Health and Stanelco plc.

Peter Glynn-Jones, said: “There are few individuals in the world with George’s experience and knowledge of the soft capsule production business. I have no doubt he will make a major contribution to accelerating the commercialisation of a number of our dosage form technologies and enhancing the technical capabilities of our film manufacturing facility in the USA.”

For anyone interested, this is macansy's post from MW site :-




I was lucky enough to attend the AGM today along with my broker whose office is just around the corner from where it was held...

I'm not going to go into great detail but will just post some notes that I made during the AGM plus the outcome of questions I put to Peter Glynn Jones after the AGM had finished whilst everyone was milling around.

In no particular order....

1) BPRG will continue to review possiblity of Nasdaq listing and the point was made that because the company already complies with SEC filing regulations that this would be a relatively simple exercise.

2) The appointment of George Tidy - I asked PGJ the significance of Mr Tidy's experience in the joint venture between SEO and Cardinal and was told to "draw my own conclusions"!

3) The recent placing to fund Aquafilm purchase was executed as such because of the importance of "getting in quick". BPRG were in a bidding situation for Aquafilm and could not afford the time it would have taken to raise the money through an open placing/rights offer etc...

4) Aquafilm purchase of assets was done so as not to pick up any hidden or otherwise liabilities - ie BPRG got exactly the parts of Aquafilm that they required and nothing else.

5) RF is categorically NOT used in the current line up of BPRG technologies, however the lawsuit is being pursued for additional future possible revenue streams and simply because BPRG want what they say "is rightfully theirs".

6) The name of the pharma in the OTC deal will be out by June - this is when it will have to be made known due to SEC rules and will therefore appear in the SEC filings...

7) FDA have recently made an impromptu visit to the Tampa production facility and have given it a clean bill of health

8) Brokers note will be forthcoming in the next couple of weeks. I spoke to PGJ about this after the AGM and am in no doubt that it is waiting for the SWALLOW deal to be signed. OF THIS I AM POSITIVE and also convinced that this deal will dwarf the FMC deal. Cheekily, I also asked him about rumours that Wyeth were the company involved in the deal for SWALLOW. His exact words were, "Wyeth? I've never worked for them!!" Now, make of this what you will but in my mind when the announcement comes through the name Glaxo will be on the RNS. He also confirmed that we will know the name of the company involved at the time of the RNS, unlike the OTC deal.

9) The OTC deal for Tabwrap is for one market sector only. I think, according to my notes, that it was store brands. I did not realise this before and therefore assume that there is much more scope for further TABWRAP deals?

10) I asked PGJ after the AGM about Far East markets. His words were that they were concentrating on "The fruit that hangs lower down first" but that the Far East, Japan, etc would be tackled in due course but that it made much better business sense to concentrate on markets that are easier to penetrate.

11) No approaches have been made to the company with regards to takeover talks.

12) Convatec share of $1 billion ostomy market is $440 million. The product development is continuing well but no revenue is likely for 2004


I'm sure there is plenty i've missed but these are some of the points I picked up. I was mightily impressed with PGJ and his willingness to answer questions once the main forum for such had closed